TSHomas are rare ,accounting for 0.5-3% of pituitary tumours [1,2]. 70-80% secrete only TSH, while 20-25% co-secrete predominantly prolactin and GH [1,3]. Almost all express somatostatin receptors , hence somatostatin
Introduction
analogues are routinely used as 2nd line treatment after surgery [4] . Post operative cure is expected in more than half of macroadenomas & almost all microadenomas [6] . We describe a recent interesting case of plurihormonal TSHoma from Oxford.
Presentation
A 22 year old lady with previous gestational diabetes presented with Haemophilus Influenza meningitis. MRI revealed an incidental pituitary macroadenoma extending
Treatment
Pending trans sphenoidal surgery, Lanreotide was started which normalised thyroid function and IGF-1. However after 2 months treatment she developed a CSF leak and a second episode of meningitis. OGTT (nadir GH 0.88 g/L) and GH day curve (mean GH 7.2 g/L ) confirmed acromegaly along with possible TSH co-secretion.
Pre
After treatment and resolution of meningitis she had trans sphenoidal adenomectomy. A patch repair was fashioned to prevent further CSF leak on SSA treatment. Histology showed a plurihormonal atypical tumour with 30% expression for GH, 1% expression for TSH and Prolactin and MIB-1 index of 5-10%. After surgery, T3, T4 and TSH remained in normal range at 5.1 pmol/L, 14.7 pmol/L and 1.68 munit/L respectively, however, IGF-1 level started to rise above the normal range at 56.4 nmol/L. Hence she has been started on Lanreotide Autogel 120mg SC four weekly. This has lead to normalisation of IGF-1. Histology demonstrated a neuroendocrine neoplasm with mitoses (arrow; usually absent in pituitary adenomas), diffuse synaptophysin expression (indicating presence of neurosecretory granules) and strong TSH expression.
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